Loading organizations...
§ Private Profile · San Diego, CA, USA
Suneva Medical is a technology company.
Suneva Medical is a privately-held aesthetics company that develops, manufactures, and commercializes novel, differentiated regenerative products. These medical devices cater to the dermatology, plastic, and cosmetic surgery markets, serving both physicians and patients. The company operates as a commercial-stage entity, focused on the aesthetics market within the United States.
The company was founded in 2015. While specific founding individuals and their precise initial insight are not explicitly detailed in publicly available snippets, Suneva Medical emerged with a clear objective to innovate within the aesthetic medical field. Early leadership focused on building the organization to deliver advanced solutions in this space.
Suneva Medical primarily serves practitioners in dermatology, plastic surgery, and cosmetic surgery, who then treat patients seeking aesthetic improvements. The company's long-term vision centers on advancing the field of regenerative aesthetics through continuous development and commercialization of its unique product portfolio, aiming to shape the future of this specialized medical area.
Suneva Medical has raised $150.4M across 5 funding rounds.
Suneva Medical has raised $150.4M in total across 5 funding rounds.
Suneva Medical has raised $150.4M across 5 funding rounds. Most recently, it raised $15.0M Other Equity in September 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 27, 2021 | $15M Venture Round | Avenue Venture Opportunities | — | Announced |
| Jun 14, 2016 | $25M Venture Round | — | — | Announced |
| Jul 29, 2015 | $35.4M Debt Financing | — | Almirall, Healthcare Royalty Partners, Polaris Partners | Announced |
| Jan 9, 2014 | $55M Debt Financing | Brian Chee | Comerica Bank, Healthcare Royalty Partners | Announced |
| Jan 1, 2014 | $20M Series B | — | Polaris Partners, Rivervest | Announced |
Suneva Medical has raised $150.4M in total across 5 funding rounds.
Suneva Medical's investors include Avenue Venture Opportunities, Almirall, HealthCare Royalty Partners, Polaris Partners, Brian Chee, Comerica Bank, RiverVest.
Suneva Medical is a privately-held medical technology company specializing in regenerative aesthetics, developing, manufacturing, and commercializing novel products like dermal fillers, autologous fat transfer systems, and platelet-rich plasma (PRP) platforms to address aging-related aesthetic concerns using the body's restorative capacity.[1][2][3][6] Its flagship product, Bellafill, is the longest-lasting FDA-approved dermal filler for nasolabial folds and acne scars, serving physicians and patients in non-surgical outpatient settings with minimally invasive solutions.[1][4][6] The company targets the growing regenerative aesthetics market, projected to reach $11 billion by 2025, with a portfolio of "first-to-market" and "only" products backed by FDA approvals, though recent product lines including Bellafill, Silhouette Instalift, and Amplifine PRP were acquired by Tiger Aesthetics.[3][6][7]
Founded in 2009 in San Diego, California (formerly Artes Medical), Suneva Medical emerged as a leader in regenerative aesthetics by focusing on differentiated products for the aesthetic medicine market.[2][3][4] Key early milestones include launching Bellafill as its flagship regenerative dermal filler and expanding through strategic partnerships in 2019 with Healeon Medical for HD PRP (FDA-cleared for platelet concentrates) and Bimini Technologies (Puregraft) for fat grafting systems, broadening its portfolio under CEO Preston Romm at the time.[1][4] Leadership later transitioned, with Pat Altavilla as CEO highlighting the company's evolution toward innovative, science-backed solutions; a 202X merger agreement with Viveon Health Acquisition Corp. aimed to fuel growth as a pure-play regenerative aesthetics firm, though by 2025, core assets were acquired by Tiger Aesthetics, marking a pivotal shift.[6][7]
Suneva Medical rides the regenerative aesthetics trend, capitalizing on rising demand for non-surgical, biology-driven treatments that harness autologous cells (e.g., PRP, fat grafts) over traditional fillers or lasers amid aging populations and minimally invasive preferences.[1][6][7] Timing aligns with market growth to $11B by 2025, fueled by clinical validations and FDA clearances that build trust in regenerative medtech.[3][6] Favorable forces include expanding aesthetic providers seeking "natural" outcomes and synergies with partners like Tiger Aesthetics, which absorbed its lines to dominate global portfolios amid consolidation.[7] It influences the ecosystem by pioneering biostimulatory tech, setting standards for regenerative integration in skincare, injectables, and body contouring.
Post-2025 acquisition by Tiger Aesthetics, Suneva's legacy products like Bellafill integrate into larger portfolios, amplifying global reach and manufacturing scale while Tiger launches adipose innovations like alloClae.[7] Trends shaping its trajectory include surging regenerative demand, AI-driven personalization in aesthetics, and regulatory tailwinds for cell-based therapies. Influence may evolve through Tiger's ecosystem, sustaining Suneva's pioneering role in natural, long-lasting aesthetics—reinforcing its origin as a shaper of regenerative futures.[1][7]